Spondylitis
Pipeline Programs↗
Active Trials↗
Companies Involved↗
Spondylitis is an emerging landscape with 11 programs across 8 companies. The most active players are Amgen, Alnylam Pharmaceuticals, Dexcel Pharma Technologies Ltd.. 7 therapies are approved.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Amgen
1 program
Alnylam Pharmaceuticals
1 program
Dexcel Pharma Technologies Ltd.
1 program
Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
1 program
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
1 program
Johnson & Johnson
1 program
Pipeline
Programs by Phase
Analysis
Modality Breakdown
82%
Small molecule
9 of 11 classified programs — the dominant modality here.
Small molecule leads; the ring shows all 11 classified programs, each share of the total. Modality classified for 100% of 11 pipeline programs.
Analysis
Trial Status
1
clinical trials
Clinical Trials
Trial Activity
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)